Signaling: Cellular insights into the pathophysiology of bipolar disorder

Biological Psychiatry

Volumn 48, Issue 6, 2000, Pages 518-530

  Manji, Husseini K ^a   Lenox, Robert H ^b  

^a Lab of Molecular Pathophysiology   (United States)

^b Molec Neuropsychopharmacology Prog   (United States)

Author keywords

Bipolar disorder; G proteins; Grotein kinase A; Lithium; protein kinase C; Signal transduction

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; CARBAMAZEPINE; COCAINE; CYCLIC AMP; DEXAMETHASONE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LITHIUM; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

AMYGDALOID NUCLEUS; ANIMAL MODEL; CALCIUM CELL LEVEL; CINGULATE GYRUS; DIAGNOSTIC IMAGING; DISEASE COURSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KINDLING; MANIC DEPRESSIVE PSYCHOSIS; MOOD; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GTP-BINDING PROTEINS; HUMANS; ION PUMPS; LITHIUM; NEURAL PATHWAYS; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 0034666355     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)00929-X     Document Type: Review

References (92)

1. Bebchuk J.M., Arfken C.L., Dolan-Manji S., Murphy J., Manji H.K. A preliminary investigation of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania. Arch Gen Psychiatry. 57:2000;95-97.
2. Berrettini W.H. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol Psychiatry. 48:2000;531-538.
3. Bhalla U.S., Iyengar R. Emergent properties of networks of biological signaling pathways. Science. 283:(5400):1999;381-387.
4. Bourne H.R., Nicoll R. Molecular machines integrate coincident synaptic signals. Cell. 72:(suppl):1993;65-75.
5. Bowden C.L. Toward an integrated biological model of bipolar disorder. Young L.T., Joffe R.T. Bipolar Disorder Biological Models and Their Clinical Application . 1997;235-254 Marcel Dekker, New York.
6. Bunney W.E., Bunney B.G. Molecular clock genes in man and lower animals. Possible implications for circadian abnormalities in depression. Neuropsychopharmacology. 22:2000;335-345.
7. Chen G., Hasanat K.A., Bebchuk J.M., Moore G.J., Glitz D., Manji H.K. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med. 61:1999;599-617.
8. Chen G., Hawver D., Wright C., Potter W.Z., Manji H.K. Attenuation of adenylyl cyclases by carbamazepine in vitro. J Neurochem. 67:1996;2079-2086.
9. Chen G, Masana M, Manji HK (in press): Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord.
10. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (in press): Enhancement of hippocampal neurogenesis by lithium. J Neurochem.
11. Colin S.F., Chang H.C., Mollner S., Pfeuffer T., Reed R.R., Duman R.S., Nestler E.J. Chronic lithium regulates the expression of adenylate cyclase and Gi-protein alpha subunit in rat cerebral cortex. Proc Natl Acad Sci U S A. 88:1991;10634-10637.
12. Daigen A., Akiyama K., Otsuki S. Long-lasting change in the membrane-associated protein kinase C activity in the hippocampal kindled rat. Brain Res. 545:1991;131-136.
13. Depue R.A., Karuss S.P., Spoont M.R. A two-dimensional threshold model of seasonal bipolar affective disorder. Magnusson D., Ohman A. Psychopathology An International Perspective . 1987;95-123 Academic Press, Orlando, FL.
14. Divish M.M., Sheftel G., Boyle A., Kalasapudi V.D., Papolos D.F., Lachman H.M. Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate model for its antimanic action . J Neurosci Res. 28:1991;40-48.
15. Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet. 2352:(9142):1998;1754-1755.
16. Drevets W.C., Price J.L., Simpson J.R. Jr, Todd R.D., Reich T., Vannier M., Raichle M.E. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 386:1997;824-827.
17. Dubovsky S., Murphy J., Christiano J., Lee C. The calcium second messenger system in bipolar disorders Data supporting new research directions . J Neuropsychiatry Clin Neurosci. 4:1992;3-14.
18. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry. 54:1997;597-606.
19. Ebstein R.P., Oppenheim G., Ebstein B.S., Amiri Z., Stessman J. The cyclic AMP second messenger system in man The effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification . Prog Neuropsychopharmacol Biol Psychiatry. 10:1986;323-353.
20. Ehlers C.L., Frank E., Kupfer D.J. Social zeitgebers and biological rhythms. A unified approach to understanding the etiology of depression. Arch Gen Psychiatry. 45:1988;948-952.
21. Einat H, Kofman O, Belmaker RH (in press): Animal models of bipolar disorder: From a single episode to progressive cycling models. In: Myslobodsky MS, Weiner I, editors. Contemporary Issues in Modeling Psychopathology. Boston: Kluwer Academic.
22. Ellis J., Lenox R.H. Receptor coupling to G proteins Interactions not affected by lithium . Lithium. 2:1991;141-147.
23. Emamghoreishi M., Schlichter L., Li P.P., Parikh S., Sen J., Kamble A., Warsh J.J. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry. 154:1997;976-982.
24. Fields A., Li P.P., Kish S.J., Warsh J.J. Increased cyclic AMP-dependent protein kinase activity in postmortem brain from patients with bipolar affective disorder. J Neurochem. 73:1999;1704-1710.
25. Friedman E., Hoau Y.W., Levinson D., Connell T.A., Singh H. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry. 33:1993;520-525.
26. Friedman E., Wang H.Y. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J Neurochem. 67:1996;1145-1152.
27. Goodwin F.K., Jamison K.R. Manic-Depressive Illness. 1990;Oxford University Press, New York.
28. Holsboer F. Neuroendocrinology of mood disorders. Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress . 1995;957-969 Raven, New York.
29. Hough C., Lu S.J., Davis C.L., Chuang D.M., Post R.M. Elevated basal and thapsigargin stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry. 46:1999;247-255.
30. Ikonomov O., Manji H.K. Molecular mechanisms underlying mood-stabilization in manic-depressive illness The phenotype challenge . Am J Psychiatry. 156:1999;1506-1514.
31. Jensen J.B., Mikkelsen J.D., Mork A. Increased adenylyl cyclase type 1 mRNA, but not adenylyl cyclase type 2 in the rat hippocampus following antidepressant treatment. Eur Neuropsychopharmacol. 10:2000;105-111.
32. Jope R.S. Anti-bipolar therapy Mechanism of action of lithium . Mol Psychiatry. 4:1999;117-128.
33. Jope R.S. A bimodal model of the mechanism of action of lithium. Mol Psychiatry. 4:1999;21-25.
34. Jope R.S., Williams M.B. Lithium and brain signal transduction systems. Biochem Pharmacol. 77:1994;429-441.
35. Kantor L., Gnegy M.E. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther. 284:1998;592-598.
36. Kofman O., Li P.P., Warsh J.J. Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin. Pharmacol Biochem Behav. 59:1998;191-200.
37. Lenox R.H. Role of receptor coupling to phosphoinositide metabolism in the therapeutic action of lithium. Adv Exp Med Biol. 221:1987;515-530.
38. Lenox R.H., Manji H.K. Lithium. Nemeroff C.B., Schatzberg A.F. American Psychiatric Press Textbook of Psychopharmacology. 1998;379-430 American Psychiatric Press, Washington, DC. 2nd ed.
39. Lenox R.H., Watson D.G. Lithium and the brain A psychopharmacological strategy to a molecular basis for manic depressive illness . Clin Chem. 40:1994;309-314.
40. Lenox R.H., Watson D.G., Patel J., Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 570:1992;333-340.
41. Magnier C., Corvazier E., Aumont M.C., Le Jemtel T.H., Enouf J. Relationship between Rap1 protein phosphorylation and regulation of Ca2+ transport in platelets A new approach . Biochem J. 310:1995;469-475.
42. Mandell A.J., Knapp S., Ehlers C., Russo P.V. The stability of constrained randomness Lithium prophylaxis at several neurobiological levels . Post R.M., Ballenger J.C. Neurobiology of Mood Disorders. 1984;744-776 Williams & Wilkins, Baltimore.
43. Manji H.K. G proteins Implications for psychiatry . Am J Psychiatry. 149:1992;746-760.
44. Manji H.K., Chen G., Hsiao J.K., Masana M.I., Moore G.J., Potter W.Z. Regulation of signal transduction pathways by mood stabilizing agents Implications for the pathophysiology and treatment of bipolar affective disorder . Manji H.K., Bowden C.L., Belmaker R.H. Bipolar Medications Mechanisms of Action . 2000;129-177 American Psychiatric Press, Washington, DC.
45. Manji H.K., Lenox R.H. Protein kinase C signaling in the brain Molecular transduction of mood stabilization in the treatment of bipolar disorder . Biol Psychiatry. 46:1999;1328-1351.
46. Manji H.K., Moore G.J., Chen G. Lithium at 50 Have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry. 46:1999;929-940.
47. Manji HK, Moore GJ, Chen G (in press): Clinical and preclinical evidence for the neurotrophic effects of mood-stabilizing agents: Implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry.
48. Manji H.K., Potter W.Z. Monoaminergic mechanisms. Joffe R.T., Young L.T. Bipolar Disorder Biological Models and Their Clinical Application . 1997;1-40 Marcel Dekker, New York.
49. Masana M.I., Bitran J.A., Hsiao J.K., Potter W.Z. In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain. J Neurochem. 59:1992;200-205.
50. Mathews R., Li P.P., Young L.T., Kish S.J., Warsh J.J. Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. Biol Psychiatry. 41:1997;649-656.
51. Milligan G., Wakelam M. G Proteins Signal Transduction & Disease . 1992;Academic Press, San Diego.
52. Mooney J.J., Samson J.A., McHale N.L., Colodzin R., Alpert J., Koutsos M., Schildkraut J.J. Signal transduction by platelet adenylate cyclase Alterations in depressed patients may reflect impairment in the coordinated integration of cellular signals (coincidence detection) . Biol Psychiatry. 43:1998;574-583.
53. Moore G.J., Bebchuk J.M., Parrish J.K., Faulk M.W., Arfken C.L., Strahl-Bevacqua J., Manji H.K. Temporal dissociation between lithium-induced CNS myo-inositol changes and clinical response in manic-depressive illness. Am J Psychiatry. 156:1999;1902-1908.
54. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK (in press): Pharmacologic increase in human gray matter. Lancet.
55. Mork A., Geisler A. The effects of lithium in vitro and ex vivo on adenylate cyclase in brain are exerted by distinct mechanisms. Neuropharmacology. 28:1989;307-311.
56. Mork A., Geisler A., Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol. 71:(suppl 1):1992;4-17.
57. Nestler E.J., Terwilliger R.Z., Duman R.S. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem. 53:1989;1644-1647.
58. Nestler E.J., Terwilliger R.Z., Duman R.S. Regulation of endogenous ADP-ribosylation by acute and chronic lithium in rat brain. J Neurochem. 64:1995;2319-2324.
59. Nestler E.J., Terwilliger R.Z., Walker J.R., Sevarino K.A., Duman R.S. Chronic cocaine treatment decreases levels of the G protein subunits Gi alpha and Go alpha in discrete regions of rat brain. J Neurochem. 55:1990;1079-1082.
60. Newman M.E., Belmaker R.H. Effects of lithium in vitro and ex vivo on components of the adenylate cyclase system in membranes from the cerebral cortex of the rat. Neuropharmacology. 26:1987;211-217.
61. Ozaki N., Chuang D.-M. Effect of lithium on transcription factor binding in cultured cerebellar granule cells and the brain of rats. J Neurochem. 69:1997;2336-2344.
62. Ozaki N., Manji H.K., Luiberman V., Lu S., Rosenthal N., Goldman D. A naturally occurring amino acid substitution of the human serotonin (5-HT) 2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem. 68:1997;2186-2193.
63. Perez J., Tardito D., Mori S., Racagni G., Smeraldi E., Zanardi R. Abnormalities of cAMP signaling in affective disorders Implications for pathophysiology and treatment . Bipolar Disord. 2:2000;27-36.
64. Perez J., Tardito D., Mori S., Racagni G., Smeraldi E., Zanardi R. Altered Rap1 endogenous phosphorylation and levels in platelets from patients with bipolar disorder. J Psychiatr Res. 34:2000;99-104.
65. Popoli M., Brunello N., Perez J., Racagni G. Second messenger-regulated protein kinases in the brain Their functional role and the action of antidepressant drugs . J Neurochem. 74:2000;21-33.
66. Post R.M., Chuang D.-M. Mechanism of action of lithium Comparison and contrast with carbamazepine . Birch N.J. Lithium and the Cell Pharmacology and Biochemistry . 1991;199-241 Academic Press, London.
67. Post R.M., Weiss S.R.B. Neurobiological models of recurrence in mood disorder. Charney D.S., Nester E.J., Bunney B.S. Neurobiology of Mental Illness. 1999;365-384 Oxford University Press, New York.
68. Post R.M., Weiss S.R.B., Clark M., Chuang D.M., Hough C., He L. Lithium, carbamazepine and valproate in affective illness Biochemical and neurobiological mechanisms . Manji H.K., Bowden C.L., Belmaker R.H. Bipolar Medications Mechanisms of Action . 2000;219-248 American Psychiatric Press, Washington, DC.
69. Rahman S., Li P.P., Young L.T., Kofman O., Kish S.J., Warsh J.J. Reduced [3H] cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem. 68:1997;297-304.
70. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 45:1999;1085-1098.
71. Rasenick M.M., Chen J., Ozawa H. Effects of antidepressant treatments on the G protein-adenylyl cyclase axis as the possible basis of therapeutic action. Manji H.K., Bowden C.L., Belmaker R.H. Bipolar Medications Mechanisms of Action . 2000;87-108 American Psychiatric Press, Washington, DC.
72. Risby E.D., Hsiao J.K., Manji H.K., Bitran J., Moses F., Zhou D.F., Potter W.Z. The mechanisms of action of lithium. Arch Gen Psychiatry. 48:1991;513-524.
73. Shibata K., Morita K., Kitayama S., Okamoto H., Dohi T. Ca2+ entry induced by calcium influx factor and its regulation by protein kinase C in rabbit neutrophils. Biochem Pharmacol. 52:1996;167-171.
74. Si-Tahar M., Renesto P., Falet H., Rendu F., Chignard M. The phospholipase C/protein kinase C pathway is involved in cathepsin G-induced human platelet activation comparison with thrombin . Biochem J. 313:1996;401-408.
75. Spiegel A.M. G Proteins, Receptors, and Disease. 1998;Humana Press, Totowa, NJ.
76. Spleiss O., van Calker D., Scharer L., Adamovic K., Berger M., Gebicke-Haerter P.J. Abnormal G protein alpha(s)- and alpha(i2)-subunit mRNA expression in bipolar affective disorder. Mol Psychiatry. 3:1998;512-520.
77. Steketee J.D., Kalivas P.W. Sensitization to psychostimulants and stress after injection of pertussis toxin into the A10 dopamine region. J Pharmacol Exp Ther. 259:1991;916-924.
78. Wang H.Y., Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry. 40:1996;568-575.
79. Wang H.Y., Friedman E. Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacology. 38:1999;403-414.
80. Wang J.F., Asghari V., Rockel C., Young L.T. Cyclic AMP responsive element binding protein phosphorylation and DNA binding is decreased by chronic lithium but not valproate treatment of SH-SY5Y neuroblastoma cells. Neuroscience. 91:1999;771-776.
81. Wang J.F., Young L.T., Li P.P., Warsh J.J. Signal transduction abnormalities in bipolar disorder. Joffe R.T., Young L.T. Bipolar Disorder Biological Models and Their Clinical Application . 1997;41-79 Marcel Dekker, New York.
82. Warsh J.J., Young L.T., Li P.P. Guanine nucleotide binding (G) protein disturbances in bipolar affective disorder. Manji H.K., Bowden C.L., Belmaker R.H. Bipolar Medications Mechanisms of Action . 2000;299-329 American Psychiatric Press, Washington, DC.
83. Watson D.G., Lenox R.H. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells Potentiation by muscarinic receptor activation . J Neurochem. 67:1996;767-777.
84. Watson D.G., Watterson J.M., Lenox R.H. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells. A property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther. 285:1998;307-316.
85. Wehr T.A., Goodwin F.K. Biological rhythms in manic-depressive illness. Wehr T.A., Goodwin F.K. Circadian Rhythms in Psychiatry. 1983;129-184 Boxwood Press, Pacific Grove, CA.
86. Wehr T.A., Goodwin F.K. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry. 144:1987;1403-1411.
87. Weintraub B.D. Molecular Endocrinology Basic Concepts and Clinical Correlations . 1995;Raven, New York.
88. Weng G., Bhalla U.S., Iyengar R. Complexity in biological signaling systems. Science. 284:(5411):1999;92-96.
89. Wiborg O., Kruger T., Jakobsen S.N. Region-selective effects of long-term lithium and carbamazepine administration on cyclic AMP levels in rat brain. Pharmacol Toxicol. 84:1999;88-93.
90. Wright A.F., Crichton D.N., Loudon J.B., Morten J.E., Steel C.M. Beta-adrenoceptor binding defects in cell lines from families with manic-depressive disorder. Ann Hum Genet. 48:1984;201-214.
91. s α protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem. 61:1993;890-898.
92. Young L.T., Woods C.M. Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells. Eur J Pharmacol. 309:1996;215-218.